Annals of Internal MedicineTiming of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain

Pegfilgrastim-induced bone pain affects a significant share of breast cancer patients receiving chemotherapy, yet no standard treatment exists. This phase 3 RCT tested whether delaying pegfilgrastim administration to 72 hours post-chemotherapy reduces bone pain without compromising neutropenia protection.

Clinical Considerations

• 72-hour administration cut severe bone pain incidence by more than half, from 58.5% (24-hour) and 66.0% (48-hour) to 22.6%, a clinically meaningful reduction
• Neutropenia rates did not differ significantly across timing groups, and no febrile neutropenia occurred in any arm, supporting safety of the delayed approach
• Study was open-label, single-center, and limited to chemo-naive stage I-III breast cancer patients — generalizability to other cancer types or regimens requires caution
• Current standard practice defaults to 24-hour administration; this trial challenges that convention with prospective, randomized evidence

Practice Applications

• Consider 72-hour pegfilgrastim timing for breast cancer patients at elevated risk for bone pain
• Discuss timing options with patients during chemotherapy counseling, particularly those with prior PIBP or low pain tolerance
• Monitor neutropenia outcomes when adopting delayed administration until broader real-world data emerge
• Evaluate applicability to patients outside the trial population before extending protocol changes

More in Pain Management